Aktis Oncology Stock

aktisoncology.comHealthcareFounded: 2019

Aktis Oncology is a biopharma solutions company that specializes in cancer care with novel platform technologies. Aktis Oncology uses powerful, radiopharmaceuticals to target therapies that harness alpha-emitting participles designed to optimize treatment options.

Register for Details

For more details on financing and valuation for Aktis Oncology, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Aktis Oncology.

Register Today

Aktis Oncology investors also invested in these private companies

Team

Management Team

Matthew Roden, PhD
President & Chief Executive Officer
Paul L. Feldman, PhD
Chief Scientific Officer
Pankaj Bhargava, MD
Interim Chief Medical Officer
Brian Goodman, PhD
Co-Founder & Chief Operating Officer
Ved Srivastava, PhD
Vice President, Head of Chemistry
Karen McCarthy
Executive Director, Head of Finance
Tyler Benedum, PhD
Senior Vice President, Head of Chemistry, Manufacturing, and Controls
Dasa Lipovsek, PhD
Vice President, Head of Lead Discovery
Kelly Polanco
Vice President, Head of People & Culture
Carlos Rodriguez
Executive Director, Corporate Development
Lorraine Horgan
Executive Director, Head of Program Management
Janet Horton, MD
Executive Director, Clinical Development

Board Members

Todd Foley
MPM Capital
Helen Kim, MBA
Vida Ventures
Oleg Nodelman
EcoR1 Capital
Lloyd M. Segal, MBA
Repare Therapeutics

Other companies like Aktis Oncology in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

Biotech firm Aktis Oncology announced Thursday it closed an $84 million extension round partially funded by large pharma companies like Merck, Bristol Myers Squibb and Novartis.